Exciting Phase 2 results with ensifentrine dry powder inhaler formulation

Runtime: 06:23

Ensifentrine offers potential benefits to COPD sufferers Verona Pharma CEO Jan-Anders Karlsson tells Proactive.

 

RPL554: the potential

RPL554: the potential

Ensifentrine: The story so far

Ensifentrine: The story so far

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us